Efficacy and safety of supplement containing Panax notoginseng on glucose and lipid metabolism -a parallel randomized trial-

Efficacy and safety of supplement containing Panax notoginseng on glucose and lipid metabolism -a parallel randomized trial- - Supplement containing Panax notoginseng on glucose and lipid metabolism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031434

Enrollment

Registered

2019-02-23

Start date

2018-02-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Supplements containing Panax notoginseng (245mg of the Panax notoginseng /tab) Placebo supplements not containing Panax notoginseng Supplements containing Panax notoginseng of double the amount (245

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) persons who is generally judged as healthy (2) persons who feel change in their body shapes and/or disturbance of the life

Exclusion criteria

Exclusion criteria: (1) persons who have any dietary supplements, quasi drugs or medicines which cause same or similar efficacy with the effect evaluated in this study (2) persons who have changed their habitats to take supplements within past 4 weeks. (3) Persons who work in night shift or in day and night shift (4) persons who have been treated their illness or prevention in a clinic at their informed consent (5) persons with their medical histories as follows: serious diseases of sugar metabolism,lipid metabolism, hepatic function, renal function, heart, circulatory, respiratory, endocrine system, immune system, or mental illness of the nervous system (6) persons with the medical histories of alcoholism or drug dependence (7) persons who might be developed allergic reaction to foods. (8) Persons who are pregnant, breast-feeding, or hope to be pregnant during the study period (9) persons who had always participated in or will participate in any other clinical trial (to use foods/medicine/quasi medicine/medical device) (10) persons who will not be judged suitable to the participants by the investigator.

Design outcomes

Primary

Measure	Time frame
Sugar metabolism(Glucose,HbA1c) Lipid metabolism(HDL-cholesterol,Total cholesterol,Triglycerides)	—

Secondary

Measure	Time frame
Hepatic function(TP,ALB,GOT,GPT, gamma-GTP,ALP) Renal function(Ureanitrogen, Creatine,Uric acid) Physical measurements (Body Height,Body weight, Body fat percentage, waist circumference, systolic bloodpressure, diastolic blood pressure, heart beat)	—

Countries

Japan

Contacts

Public ContactKuniyoshi Shimizu

Faculty of Agriculture, Kyushu University Laboratory of Systematic Forest and Forest Products Science

shimizu@agr.kyushu-u.ac.jp0926423002

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026